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To examine the features of available Framingham-
based risk calculation tools and review their accuracy and fea-










search engine on the Internet.
 
TOOL AND STUDY SELECTION:
 
We included risk calculation
tools that used the Framingham risk equations to generate a
global coronary heart disease (CHD) risk. To determine tool
accuracy, we reviewed all articles that compared the perform-
ance of various Framingham-based risk tools to that of the
continuous Framingham risk equations. To determine the
feasibility of tool use in clinical practice, we reviewed articles
on the availability of the risk factor information required for
risk calculation, subjective preference for 1 risk calculator




Two reviewers independently reviewed
the results of the literature search, all websites, and abstracted




Multiple CHD risk calculation tools are
available, including risk charts and computerized calculators
for personal digital assistants, personal computers, and web-
based use. Most are easy to use and available without cost.
They require information on age, smoking status, blood pres-
sure, total and HDL cholesterol, and the presence or absence
of diabetes. Compared to the full Framingham equations, accu-
racy for identifying patients at increased risk was generally




Several easy-to-use tools are available for esti-
mating patients’ CHD risk. Use of such tools could facilitate
better decision making about interventions for primary pre-
vention of CHD, but further research about their actual effect




Drs. Sheridan and Pignone have participated in
the development of Heart-to-Heart, one of the risk tools evalu-
ated within. They have also received speaking and consulting





risk assessment; coronary heart disease; Fram-
ingham Heart Study.
 




linical practice guidelines recommend that providers
and patients base treatment decisions regarding cor-
onary heart disease (CHD) prevention on assessment of




 In addition, the American
Heart Association has recommended that adults aged 40
and older with no previous history of cardiovascular dis-




To implement these guidelines in clinical practice, provid-
ers need an accurate and feasible means of calculating
global CHD risk.
Previous research has shown that providers do not




Fortunately, multivariate risk prediction equations have
been developed to better estimate CHD risk. These equa-
tions have been derived from large prospective cohort stud-




 and estimate a patient’s risk
of having a CHD event over 5 to 10 years. They provide bet-
ter estimates of CHD risk than either assessment of single
risk factors or simple counting of multiple risk factors and





 Some of the available risk equations, however,
have limitations: they include relatively few risk factors; are
derived from truncated middle-aged or male-only popula-
tions; use logistic regression models that require fixed
follow-up periods (e.g., 10 years); treat events occurring at
1 year the same as events occurring at 5 or 10 years; and
have been prospectively validated in limited populations.
Among the various risk prediction equations, those
derived from the Framingham Heart Study are most com-





equations calculate the absolute risk of CHD events for
patients with no known previous history of CHD, stroke,
or peripheral vascular disease (primary prevention). Com-
pared to other risk equations, the Framingham risk equa-
tions have favorable characteristics: they were developed
in a large prospective cohort of U.S. men and women aged
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 and discriminate well among




In general, the Framingham equations also predict the
degree of risk well in middle-aged white and African-American
adults, although hypertension is somewhat underweighted










 The equations predict the degree of
risk less well in men and women younger than age 30 or





 They also are less precise in
patients with diabetes, severe hypertension, or left ven-
tricular hypertrophy because fewer numbers of participants




For use in clinical practice, the Framingham equations
have been operationalized into several risk assessment
“tools.” Common formats of available risk tools include risk
charts (simple tables or wall charts) and electronic calcu-
lators, which are available as stand-alone applications for
personal computers or personal digital assistants, and web-
based tools. We sought to review available CHD risk calcula-
tion tools based on Framingham equations to help guide




To identify Framingham-based CHD risk calculation
tools and review their accuracy and feasibility in clinical





2003 using the MeSH terms coronary heart disease and
risk assessment. To identify web-based tools that are read-
ily available to the clinician, we also performed an Internet





and the search term “cardiac risk calculator.” Finally, we
used our own literature files, and hand-checking of iden-
tified bibliographies and web links to identify other risk
tools or articles evaluating risk assessment tools.
To identify available CHD risk calculation tools, we
included articles and websites that used the Framingham
risk equations to generate a global CHD risk, expressed
either as the proportion of similar patients who would have
a CHD event over a defined time period or as the movement
of a patient across a predefined treatment threshold. We
excluded articles and websites that used non-Framingham
risk equations, did not specify the equation used for cal-
culation, were designed for secondary prevention, did
not clearly define the calculated risk outcome, or calculated
risk using nontraditional risk factors such as blood type
or measures of psychological stress.
To determine the accuracy of CHD risk tools, we
included articles that compared the performance of various
Framingham-based risk tools to that of the continuous
Framingham equation in clinical practice. We included
articles that tabulated the sensitivity and specificity of the
risk tools or provided enough information that these could
be calculated.
Because we wanted to focus on tools available for
clinical practice, we excluded articles that compared
the discriminatory and predictive abilities of continuous
Framingham equations including different risk factors or
prospectively examined the continuous Framingham equa-
tions in large epidemiological study populations. We also
excluded articles that examined the accuracy of non-
Framingham-based risk tools, used a gold standard other
than the continuous Framingham model, or that reported
only the difference in accuracy among various provider groups.
To determine the feasibility of risk tools in clinical
practice, we included articles that provided information on
the availability of the risk factor information required for
risk calculation, subjective preference for one risk calculator
over another, or subjective ease of use of the various risk
calculators.
Two of us independently reviewed the results of the lit-
erature and web searches (MP, SS) to determine article and
website inclusion. We then abstracted relevant information
from included articles and websites into tables for analysis
(CM, MP, SS). Disagreements were resolved by discussion
among team members.
We categorized the risk tools into 2 main groups:
1) risk charts (usually printed); and 2) electronic calculators,
including computer programs for personal digital assis-
tants (handheld PDAs), spreadsheet programs designed to
run on personal computers, and web-based risk calcula-
tors. We then reviewed each tool to determine the required
input and to characterize its output.
For studies reporting on the accuracy and feasibility
of various risk calculators, we abstracted information that
we felt would impact the quality of the accuracy estimates
reported and their applicability to clinical practice. Specifi-
cally, we abstracted information on the identity of the risk
scorer, whether they were blinded to the gold standard
risk assessment, what patient population was used for risk
assessment, whether all necessary patient data were avail-
able for the risk calculation, and what reference cutpoint
was used to distinguish high versus low CHD risk. We










 search identified 1,306 articles on risk
assessment for coronary heart disease and our final Inter-
net search, conducted on April 28, 2002, identified 3,690
websites. After review of abstracts and potentially relevant
articles, we included 8 articles describing Framingham-
based risk calculation tools and 7 articles providing infor-
mation on the accuracy and feasibility of the tools. Two
independent reviewers additionally reviewed the 100 web-




search engine, including 10 sites described in this report.
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 = 3). Forty of the




Table 1 provides a representative, but not exhaustive,
sample of available tools. Tools have a variety of formats
including risk charts (simple tables or wall charts) and elec-
tronic calculators, which are available as stand-alone or
web-based applications for personal computers, or as
stand-alone applications for personal digital assistants. All
tools require information on age, gender, total cholesterol,
systolic blood pressure, and smoking status for risk cal-
culation; most also include diabetes, assessed as a yes/no
answer, and high-density lipoprotein (HDL) cholesterol.
Some tools using older versions of the Framingham equa-
tions also prompt input on the presence of left ventricular
hypertrophy (LVH) on electrocardiogram, although lack of
this information does not preclude risk calculation.
The output of the risk tools we reviewed is diverse.
CHD events are defined alternately as a composite of myo-
cardial infarction (nonfatal or fatal) and sudden death or
as new-onset stable angina, unstable angina (called “cor-
onary insufficiency” in the Framingham study), myocardial
infarction, and sudden death. Some tools (e.g., Sheffield
tables, Joint British charts, and Joint European charts)
estimate the risk of CHD events alone, while others (e.g.,
New Zealand tables) give risks for CHD events and for
stroke. One tool (Birmingham Heartlands Calculator) also
included peripheral vascular disease as an outcome.
The presentation of CHD risk (see Fig. 1) is generally
in numeric or graphic terms, with few tools including
written explanation of the results. Some tools (e.g., New
Zealand tables) give a point estimate of risk, whereas
others provide a range of risks or simply state whether a
predefined treatment threshold to initiate therapy had
been exceeded (e.g., Sheffield tables). Most tools provide
either a comparison to the risk of an individual of the same
age or gender who has no risk factors or to an individual
with “average” risk factors. Many also provide a qualitative
description, such as high or low risk. A minority provide





Several different risk charts are available in
print form or from the Internet. The charts (or tables) gen-
erally fall into 2 types: 1 type assigns points to various
levels of each risk factor and then assigns a specific risk
for the total score obtained after summing the individual
scores for each risk factor (e.g., Categorical Framingham
tables). The second type arrays information in various com-
binations of columns and rows either to allow a specific
risk to be read from the chart (e.g., New Zealand tables) or
to reach a treatment decision given a predefined threshold
for treatment (e.g., Sheffield tables). The main advantage
of tables and charts is that they do not require a computer
for use. They can be downloaded, printed, or photocopied
and used in any setting. The main downsides are that they
may be difficult or time consuming to use at first and that
they are not as accurate or precise as some of the spread-
sheet or web-based calculators described below.
 
Tools for Personal Digital Assistants (PDAs).
 
Currently, few
risk tools are available for handheld computers or PDAs
(e.g., Stat Cardiac Risk, the National Cholesterol Education
Program Palm Calculator, FramPlus, and Heart-to-Heart).
Based on the updated Framingham risk equations, these
programs use categorical classification of risk factors to




 Because they use
ranges, they are slightly less precise than some of the
spreadsheet calculators that use exact values. On the pos-
itive side, they are portable and very easy and fast to use
and can be shared with other PDA users by simply “beam-
ing” the program via the infrared port.
 
Spreadsheet Calculators for Personal Computers.
 
Spreadsheet-
based calculators make the Framingham equations
available in a computer program such as Microsoft Excel
(Microsoft Corporation, Redmond, WA). They require that
the spreadsheet program be installed on each computer
that is to be used for calculating risk. One commercial pro-
duct, the BMJ CardioRisk Manager, adds the capability of
producing more sophisticated reports (including a letter to
send results to the patient) and can archive results. It also
includes a “slider bar” to allow patients and providers to
see the projected effect of treatment on CHD outcomes. The
expected effect of treatment is demonstrated by recalculat-
ing risk using posttreatment risk factor levels rather than
by applying the best evidence about expected risk reduc-
tion to baseline calculated risk. This may be misleading
because changes in risk levels with treatment do not pro-
duce the same degree of risk reduction as would be pre-
dicted from observational studies. Another calculator, the
Birmingham Heartlands Calculator, does estimate the effect





Several web-based risk calcula-
tors are available. They require that the user have Internet
access, but no local software is needed other than a web
browser. They can only be used effectively in practice set-
tings that have continuous access to the Internet; estab-
lishing a dial-up connection each time the program is used
is impractical. Web-based calculators generally use the full
Framingham equation. Results can be printed from the
browser to be placed in the medical record. Additionally,
a few tools (the risk calculator from the University of
Edinburgh (www.cardiacrisk.org.uk) and the Heart-to-
Heart tool (www.med-decisions.com) offer the option to
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FIGURE 1. Examples of the information presented in Framingham-based risk calculation tools.
 















Studies that Assess the Accuracy of Various 
Framingham-based Risk Calculators and the 
Feasibility of Their Use in Clinical Practice
 
We found 6 studies that compared the relative accu-
racy of various risk prediction charts or tables with full





tronic calculators use the full Framingham equation or
tally scores from charts or tables, we found no studies
separately examining these tools. In the studies we iden-
tified, risk assessors calculated CHD risk from data
obtained from patient charts, physical examinations, and
laboratory assessments; the standard for comparison was





sors were practicing clinicians with no prior knowledge of
the results of the full Framingham calculation. In the
remaining 4 studies, the risk assessors were computer




We could not tell whether these risk assessors had prior
knowledge of the Framingham equations or the risk cal-
culation tools or whether they received any special training
in their use.
Table 3 gives reported sensitivity and specificity values
for the most commonly used risk assessment tools from
the 6 studies. Although all studies used full Framingham
equations as the reference standard, different cutpoints
were sometimes used to define high-risk status or thresh-
olds for treatment. We include the results for the most com-
mon cutpoints here. In general, the tools displayed good
to excellent sensitivity and specificity for detection of
patients with increased CHD risk. Only the Canadian tool
had poor accuracy in predicting a risk of greater than 3%
per year; it performed much better at a reference standard









make no comparisons of sensitivity and specificity findings
across studies due to the varying numbers of indeterminate
assessments, different reference standard cutpoints, and
diverse study populations.
The proportion of insufficient data available to com-
plete the Framingham calculations varied from 5% to 49%
across studies, including 11% to 49% of cases in the 1 study





 When data were missing, none of the study
authors used mean risk factor values to estimate risk. The
most common reason for inability to assess patient risk was
missing HDL cholesterol values. Thus, risk assessments
that do not require HDL values (Joint European charts)
were completed more often than those that rely on HDL





 examined the reliability of
the risk calculations of general practitioners and practice




 values ranging from 0.47 to 0.58, sug-
gesting moderate reliability. In the same study, however,
risk assessments were inappropriately completed for 40%
of patients with known coronary heart disease, even though
such patients can be classified as high-risk based on dis-
ease history alone.
We found 1 additional Scottish study that compared
the calculations from 3 risk assessment tools (New Zealand
table, old Sheffield table, and Joint British chart) with each
other, rather than with full Framingham equation esti-
mates, and provided information about the feasibility of




 In this study, a self-
nominated general practitioner and nurse from each of 37
general practices completed risk assessments on a set of
12 case histories that reflected varying levels of CHD risk.
Doctors and nurses preferred New Zealand tables and Joint
British charts over the Sheffield tables and found them eas-
ier to use. Doctors generally scored case histories with simi-
lar risks using the 3 different risk tools, while accuracy
among nurses was significantly poorer with the Sheffield




Policy-making bodies increasingly agree that the most
efficient and effective clinical CHD prevention requires a




 Fortunately, a variety
of user-friendly tools based on the Framingham equation
are available to help clinicians perform CHD risk assess-
ment for patients with no known history of cardiovascular
disease. Our review suggests that, in general, the categori-
cal charts and tables derived from the Framingham equa-
tion are accurate and feasible for use in clinical settings
and can be used in lieu of the continuous Framingham cal-
culators when necessitated by the clinical environment.
This supports findings by chart developers who report sim-





 Some features of the computer
or PDA-based tools, however, may make them a better
choice for providers with access to such devices.
In deciding among available tools, providers may wish
to choose tools that provide risk information in a format
that can be used with current guidelines for risk reduction
(see Table 4). For instance, to allow risk-based decision
making about lipid-lowering therapy, providers need a tool









 All of the spreadsheets, PDA, and web-based cal-
culators have this capability because all use the continu-
ous Framingham equations or the original Framingham
categorical charts. Many of the risk charts also have this
capability; the notable exception is the Modified Sheffield
table, which uses only 15% and 30% cutoffs. To adhere to
evidence-based guidelines on aspirin use, providers need
a tool with finer gradations of risk because the risk/benefit
ratio for aspirin use transitions from helpful to harmful





 This again reduces the number of useful risk
charts, but still allows many acceptable options. At
present, it is unclear how providers should address risk
calculation in patients with diabetes. The National Choles-
terol Education Program and the American Heart Associ-
ation currently recommend that physicians treat patients































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 In accordance with this, they have recom-
mended that their Framingham risk calculators be used
only in patients without diabetes. At present, however, we
are unaware of direct evidence that suggests this strategy
is more effective than relying on calculated risk assessment,
and many calculators continue to request input of diabetes
status for risk calculations.
In choosing which risk tool to use, providers should
consider their practice environment and who will be per-
forming the risk assessments. Providers who have access
to a computer with an available spreadsheet program or
dedicated high-speed Internet access line should consider
spreadsheet and web-based programs for risk calculation.
These tools allow calculation of fine gradations of risk,
frequently provide comparisons to individuals with low
risk (e.g., BMJ Cardiorisk Manager, Birmingham Heartlands
Calculator, National Cholesterol Education Program Risk
Calculator, RiskCalculator from the Center for Cardiovas-
cular Sciences at the University of Edinburgh, Healing
Hearts Risk Calculator, Medical-decisions.com calculator,
and American Heart Association Calculator), and, in some
cases, provide targeted advice on treatment and allow
exploration of the effects of treatment on calculated risk
Table 3. Accuracy of Several Common Framingham Risk Tools*
Risk Tools Sensitivity, %* Specificity, %*
Percent of Indeterminate Calculations
Due to Missing Risk Tool Data, %
Reference Standard 
Cutpoint (Annual Risk), %
Joint British charts
Wierzbicki et al., 
200035 100 100 ~5 CHD risk >3
Game et al., 200123 77 99 ~15 CHD risk >3
Jones et al., 200131 85 99 ~5 CHD risk >3
McManus et al., 
200233 80 91 49
CHD risk >3
Joint European charts
Durrington et al., 
199932 Unclear Unclear 41% CHD risk >2
Wierzbicki et al., 
200035 95 100 ~5 CHD risk >2
Game et al., 200123 89 72 ~15 CHD risk >2
Jones et al., 200131 75 86 ~5 CHD risk >2
McManus et al., 
200233 63 73 17 CHD risk >2
New Zealand tables
Wierzbicki et al., 
200035 56 100 ~5
CHD risk > 2
Game et al., 200123 94 58 ~15 CHD risk >2
Jones et al., 200131
(8 categories) 83 79 ~5 CHD risk >2
McManus et al., 
200233 68 75 49
CHD risk >4
Modified Sheffield tables
Durrington et al., 
199932 Unclear Unclear 33
CHD risk >3
Wierzbicki et al., 
200035 64 100 ~5
CHD risk >3
Wallis et al., 200034 82 99  0† CHD risk >3
Game et al., 200123 96 92 ~15 CHD risk >3
Jones et al., 200131 91 96 ~5 CHD risk >3
McManus et al., 
200233 61 88 11
CHD risk >3
Canadian tables
Game et al., 200123 5 100 ~15 CHD risk >3
Jones et al., 200131 3 100 ~5 CHD risk >3
Framingham tables
Game et al., 200123 95 83 ~15 CHD risk >2.7
Jones et al., 200131 67 98 ~5 CHD risk >2.7
CHD, coronary heart disease; CVD, cardiovascular disease.
* The reference standard is the full Framingham equation; sensitivity and specificity estimates do not account for indeterminate values of
either the risk tool or the reference standard.
† Only participants who had complete data from a larger survey study were selected.
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(e.g. BMJ Cardiorisk Manager, Birmingham Heartlands
Calculator, Heart-to-Heart Calculator). Additionally, at least
one of these tools (Heart-to-Heart Calculator) is targeted
to patients and can be used independently of the clinician
visit. For providers who do not have access to these tools,
current PDA tools and risk charts offer an acceptable
option.
Some providers may find that a combination of pro-
ducts is most useful, particularly if the outcome of interest
varies according to patient concerns. Most tools provide
information on the combined risk of stable and unstable
angina, myocardial infarction, and CHD death. Some tools,
however, report only the risk of myocardial infarction and
CHD death; these tools will produce smaller numeric esti-
mates of risk than tools that also include angina. The cur-
rent NCEP risk calculator, for example, uses a set of newly
revised Framingham equations that only predict the risk
of myocardial infarction and CHD death. To our knowledge,
these equations have not been published in the peer-
reviewed literature. Other tools allow calculation of all CVD
events by adding stroke outcomes (e.g., New Zealand Risk
Table, British Cardiac Risk Assessor, BMJ Cardiorisk Man-
ager, Risk Calculator from the Center for Cardiovascular
Sciences at the University of Edinburgh) or by allowing
independent calculation of the risk of stroke and peripheral
vascular disease (e.g., Birmingham Heartlands Calculator).
In addition to choosing which type of risk tool to use,
providers must ensure that they have sufficient information
to complete the risk assessment. Some information, such
as age, smoking status, and presence or absence of dia-
betes, can be obtained by interview at the time the risk
calculation is performed. Other information, such as blood
pressure, cholesterol levels, and presence or absence of left
ventricular hypertrophy on electrocardiogram must be
obtained prior to risk calculation.
Our review identified several limitations among the
available Framingham tools. First, existing tools do not pre-
dict risk beyond 12 years. This is a limitation imposed by
the published data available from the Framingham Heart
Study. Although Framingham investigators have published
data on the lifetime risk of developing coronary heart dis-
ease,38 they have not incorporated lifetime risk into tools
for clinical risk estimation. Presentation of lifetime risks
may have different effects on perceived threat and motiva-
tion to undertake risk-reducing behavior for some patients,
particularly younger ones, who are making longer-term
prevention decisions,38–41 although to date this has not
been empirically studied. Second, none of the tools specify
how electrocardiographic LVH is to be defined, although
available evidence suggests that LVH with repolarization
abnormality (strain pattern) provides the best predictive
ability, and LVH by voltage criteria alone is not associated
with clearly increased risk.42 Third, none of the tools pro-
vide confidence intervals around risk estimates. Their
absence may convey a false sense of precision. Finally,
most tools do not provide accurate information about the
benefits and adverse effects of risk-lowering interventions,
which may limit their clinical utility.
Aside from the limitations of the tools, we acknowledge
the limitations of the Framingham equations themselves.
Although the Framingham equations predict the degree of
risk well in white and African-American men and women
between the ages of 30 and 65 in the United States, they
predict the degree of risk less well in non-U.S. populations,
certain U.S. ethnic groups (Japanese men, Hispanic men,
and Native-American women), men and women younger
than age 30 or older than age 65, and diabetic per-
sons.25,27,28 One approach to the Framingham equations’
limits is to recalibrate the tool for use in designated
target populations.28 At present, we are not aware of any
Framingham-based risk calculation tools that have
attempted to do this.
The current Framingham equations have additionally
attempted to balance accuracy and feasibility43 and hence
have limited the number of risk factors required for risk
estimation. They do not include the following established
and potential risk factors, which may be of interest: blood
glucose level, hemoglobin A1C, triglycerides, lipoprotein A,
small dense low-density lipoprotein particles, homo-
cysteine, c-reactive protein, microalbuminuria, coagulation
factors, weight or body mass index, physical activity, and
family history of premature cardiovascular disease. The
effect of adding additional risk factors to risk calculation
tools has been little studied.
Table 4. Current Guidelines for Cardiovascular Risk Reduction
Risk Factor or Risk Intervention Treatment Guideline
10-year Risk Cutoffs for Determining
Appropriate Treatment
Cholesterol National Cholesterol Education Program (NCEP)1 10%/20%
Blood pressure The sixth report of the Joint National NA; although guideline encourages
Committee on the Prevention, counting risk factors (which roughly
Detection, Evaluation, and Treatment correlates to 10%/20% of NCEP)
of High Blood Pressure4
Smoking Surgeon General’s Report on Smoking58 NA; any tobacco use requires intervention
Aspirin use US Preventive Services Task Force 2%/6%/10%
Report on Aspirin for the Prevention
of Cardiovascular Disease2
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As of April 2003, our searches of the medical literature
also show that the effect of risk calculators on clinical
practice and outcomes has not been well studied. Two
studies6,44 suggest that providing physicians with compu-
terized risk calculators has had little impact on CHD risk.
These studies, however, provided no link to evidence-based
guidelines and had important methodological limitations
including high attrition rates44 and use in populations
who already have existing CHD.6 A third study, in which
researchers alternately wrote patient risk scores on the
front of patient charts or not, also suggests the limited
effects of providing physicians with only risk estimates.45
Whether calculating and communicating global CHD risk
to patients affects their willingness or ability to change their
lifestyle and use preventive medications, such as aspirin,
antihypertensive drugs, or cholesterol-lowering medica-
tion, has not been well studied. Although a recent pilot
study46 testing the combined effects of a self-guided work-
book and physician visit on global CHD risk reported that
68% of users planned to make a variety of interventions
on their risk as a result of using the book, traditional CHD
risk appraisal has had only modest impact on actual
patient behavior in the areas of diet and exercise.47–49 One
recent study has shown reductions in CHD risk, body mass
index, and cholesterol levels at 5 years follow-up in inter-
vention groups that received CHD risk appraisal with or
without physician consultation,50 but conclusions were
limited by high attrition rates and poor participation in
follow-up consultations throughout most of the study. Fur-
ther research is still needed.
Research should also determine whether the inclusion
of newer risk factors for CHD (i.e., lipoprotein a, homo-
cysteine, micro-albuminuria, or c-reactive protein), or
noninvasive measures of atherosclerosis, such as electron-
beam computerized tomography (EBCT) or carotid Doppler
ultrasound, improves risk assessment and leads to better
use of CHD risk-reducing treatments. Some have suggested
that these novel risk factors may be best used to modify
the pretest probability estimate from the Framingham risk
score, particularly for those with intermediate risk.43
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